ClinicalTrials.gg

Program

infigratinib

Also written as “Infigratinib”, “BGJ398” and “infigratinib 0.128 mg/kg/day”.

Its studies are mostly in Achondroplasia · Mucopolysaccharidosis IV · Stomach Neoplasms · Cholangiocarcinoma · Urinary Bladder Neoplasms, led by 5 companies.

Furthest: phase 3, since Dec 10, 201817 company-led studies, 3 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BridgeBio83 open or runningphase 3since Dec 10, 2018May 12, 2014Jan 2027phase 3 · NCT06873035
Novartis50 open or runningphase 2since Oct 28, 2013Oct 27, 2009none ahead
LianBio20 open or runningphase 2since Jul 28, 2021Jul 28, 2021none ahead
Helsinn Healthcare10 open or runningphase 2since Jan 12, 2022Jan 12, 2022none ahead
Pfizer10 open or runningphase 2since Apr 28, 2014Apr 28, 2014none ahead

Also a collaborator on its studies: labcorp-corporation-of-america-holdings-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Oct 27, 2009.

  1. Oct 28, 2013Phase 2 study in GlioblastomaNovartis · NCT01975701 · 26 enrolled · United States, Australia, Belgium and more
  2. Apr 28, 2014Pfizer's first study: phase 2 study in MelanomaNew to PfizerPfizer · NCT02159066 · 158 enrolled · United States, Australia, Canada and more
  3. May 12, 2014BridgeBio's first study: phase 2 study in CholangiocarcinomaNew to BridgeBioBridgeBio · NCT02150967 · 143 enrolled · United States, Belgium, Germany and more
  4. Jun 6, 2014Phase 2 study in Hematologic NeoplasmsNovartis · NCT02160041 · 84 enrolled · United States
  5. Dec 10, 2018Phase 3 study in CholangiocarcinomaBridgeBio · NCT03773302 · 48 enrolled · United States, Australia, Belgium and more
  6. Dec 2, 2019Phase 3 study in Upper Tract Urothelial CarcinomasBridgeBio · NCT04197986 · 39 enrolled · United States, Belgium, Bulgaria and more
  7. Jan 29, 2020Phase 2 study in AchondroplasiaBridgeBio · NCT04265651 · 84 enrolled · United States, Australia, Canada and more
  8. Jul 28, 2021LianBio's first study: phase 2 study in Stomach NeoplasmsNew to LianBioLianBio · NCT05019794 · 80 enrolled · China
  9. Nov 22, 2021Phase 2 study in AchondroplasiaBridgeBio · NCT05145010 · 325 planned · United States, Argentina, Australia and more
  10. Jan 12, 2022Helsinn Healthcare's first study: phase 2 study in Central Nervous System NeoplasmsNew to Helsinn HealthcareHelsinn Healthcare · NCT05222165 · United States, Canada, Germany
  11. Nov 29, 2023Phase 2 study in Stomach NeoplasmsLianBio · NCT06206278 · 6 enrolled · China
  12. Nov 29, 2023Phase 3 study in AchondroplasiaBridgeBio · NCT06164951 · 114 enrolled · United States, Argentina, Australia and more
  13. Feb 18, 2025Phase 3 study in HypochondroplasiaBridgeBio · NCT06873035 · 24 planned · United States, Australia, Canada and more
  14. Jan 19, 2026Phase 2 study in HypochondroplasiaBridgeBio · NCT07393373 · 135 planned · United States, Australia, Canada and more

Ahead

  1. Jan 2027Primary completion: phase 3 study in HypochondroplasiaBridgeBio · NCT06873035
  2. Dec 1, 2031Primary completion: phase 2 study in AchondroplasiaBridgeBio · NCT05145010
  3. May 31, 2036Primary completion: phase 2 study in HypochondroplasiaBridgeBio · NCT07393373

TargetBeta

“Fibroblast growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
futibatinibruleOtsukaphase 310

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07393373Hypochondroplasia · United States, Australia, Canada and more2By invitationBridgeBioMay 31, 2036135
NCT06873035Hypochondroplasia · United States, Australia, Canada and more3By invitationBridgeBioJan 202724
NCT06206278Stomach Neoplasms · China2TerminatedLianBioMay 31, 20246
NCT06164951Achondroplasia · United States, Argentina, Australia and more3CompletedBridgeBioDec 18, 2025114
NCT05222165Central Nervous System Neoplasms · United States, Canada, Germany2WithdrawnHelsinn HealthcareDec 16, 20220
NCT05145010Achondroplasia · United States, Argentina, Australia and more2By invitationBridgeBioDec 1, 2031325
NCT05019794Stomach Neoplasms · China2UNKNOWNLianBioDec 30, 202280
NCT04265651Achondroplasia · United States, Australia, Canada and more2CompletedBridgeBioOct 21, 202484
NCT04197986Upper Tract Urothelial Carcinomas · United States, Belgium, Bulgaria and more3TerminatedBridgeBioFeb 28, 202339
NCT03773302Cholangiocarcinoma · United States, Australia, Belgium and more3TerminatedBridgeBioMar 2, 202348
NCT02160041Hematologic Neoplasms · United States2TerminatedNovartisApr 30, 201884
NCT02150967Cholangiocarcinoma · United States, Belgium, Germany and more2TerminatedBridgeBioMar 1, 2021143
NCT02159066Melanoma · United States, Australia, Canada and more2CompletedPfizerJan 10, 2023158
NCT01975701Glioblastoma · United States, Australia, Belgium and more2CompletedNovartisOct 3, 201826
NCT01928459Breast Neoplasms · United States, Australia, Belgium and more1CompletedNovartisAug 201662
NCT01697605Tumor With Alterations of the FGF-R · China, Japan1CompletedNovartisFeb 7, 20199
NCT01004224Lung Neoplasms · United States, Australia, Austria and more1CompletedNovartisOct 8, 2018208

How it is read

Names in the registry

  • “Infigratinib”, 7 entries
  • “BGJ398”, 7 entries
  • “infigratinib 0.128 mg/kg/day”, 1 entry
  • “infigratinib 0.25 mg/kg/day”, 1 entry
  • “Infigratinib 0.25 mg/kg/day”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.